Tim Herpin, AstraZeneca: Achieving scientific leadership and restoring growth




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Tim Herpin, AstraZeneca: Achieving scientific leadership and restoring growth
Released on: October 10, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at BIO Europe in Vienna, Paul Larsmon talks to Tim Herpin, Vice President, Head of transactions, Business development, GPPS, AstraZeneca.
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at BIO Europe in Vienna, Paul Larsmon talks to Tim Herpin, Vice President, Head of transactions, Business development, GPPS, AstraZeneca. They discuss the change in strategy at AstraZeneca and how this will help them to achieve scientific leadership and restore growth. They discuss the major deals of 2013 for AstraZeneca and how these will ultimately benefit patients.
In this interview filmed at BIO Europe in Vienna, Paul Larsmon talks to Tim Herpin, Vice President, Head of transactions, Business development, GPPS, AstraZeneca. They discuss the change in strategy at AstraZeneca and how this will help to achieve scientific leadership and restore growth. They also review some of the major deals of 2013 for AstraZeneca and how these will ultimately benefit patients.
Tim Herpin
AstraZeneca
AstraZeneca
AstraZeneca plc is a British-Swedish pharmaceutical company formed on 6 April 1999 by the remerger of Swedish Astra AB and British Zeneca Group plc. Zeneca had been part of Imperial Chemical Industries (ICI), as three divisions that were spun off from ICI on 1 June 1993. It is a public company and is listed on the London Stock Exchange, the New York Stock Exchange and the OMX exchange.